Medsider: Learn from MedTech and HealthTech Experts

Demonstrating Value with Robust Clinical Trial Data: Interview with Miracor Medical CEO Olivier Delporte

August 01, 2022 Scott Nelson
Medsider: Learn from MedTech and HealthTech Experts
Demonstrating Value with Robust Clinical Trial Data: Interview with Miracor Medical CEO Olivier Delporte
Show Notes

In this episode of Medsider Radio, we sat down with Olivier Delporte, CEO of Miracor Medical.

Olivier has more than 20 years of sales, marketing, and general management experience, mostly in the medical device industry. In 2016, he became the CEO of Miracor Medical, a medical device company based in Belgium. Under Olivier’s guidance, the company is advancing its flagship PiCSO treatment for severe myocardial infarction.  

In this discussion, Olivier explains why he advocates for randomized clinical trials, how remote monitoring tools can make clinical trial programs more efficient, and why startups should increase their fundraising goals.  

Before we jump into the conversation, I wanted to mention a few things:

If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.

This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors sent to their door at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, here's the link to the full interview with Olivier if you'd rather read it instead.